Robertson Stephens Wealth Management LLC lessened its stake in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT – Free Report) by 8.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 183,786 shares of the company’s stock after selling 16,000 shares during the quarter. […]
Adaptive Biotechnologies Co. (NASDAQ:ADPT – Get Free Report) has received a consensus rating of “Moderate Buy” from the six research firms that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price […]
Peregrine Capital Management LLC lessened its holdings in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT – Free Report) by 14.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 375,638 shares of the company’s stock after selling 64,317 shares during the […]
Peregrine Capital Management LLC reduced its holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT – Free Report) by 14.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 375,638 shares of the company’s stock after selling 64,317 shares during the quarter. Peregrine Capital Management LLC […]
Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) and Ikena Oncology (NASDAQ:IKNA – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation. Volatility & Risk Adaptive Biotechnologies has a […]